UT-XLEAR
Today, Nathan Jones, CEO of Xlear, Inc. released this statement in response to a lawsuit filed by the Department of Justice, on behalf of the United States, alleging that certain statements made by Xlear violated the Federal Trade Commission Act and the Consumer Protection Act:
Last year, the Government published on the website of the National Institutes of Health the results of a clinical trial performed by researchers at Larkin Community Hospital, Florida. The Larkin clinical trial found people who were already sick with COVID-19, who used Xlear nasal spray—and just Xlear nasal spray—cleared the disease and tested negative in half the time of the average COVID-19 case. None of the patients developed severe cases, none required hospitalization. Now the Government is suing Xlear asserting, among other things, that when Xlear tells people about scientific studies, even ones republished by the NIH, we are somehow misleading people and making false claims. It’s nonsensical.
What is more troubling, despite the results of the Larkin trial, and despite the results of a Government-funded Random Clinical Trial done at Vanderbilt University, and despite the findings of yet another Random Clinical Trial done in Georgia, the Government refuses to tell the American people that washing your nose may significantly reduce your risks of getting a severe case of COVID-19, which could result in hospitalization and death.
At the same time, growing numbers of in vitro studies find Xlear, and its components, are: antiviral (blocks adhesion—infection—by COVID-19); virucidal (kills and/or deactivates the COVID-19 virus); and, antibacterial (help prevent pneumonia, a leading COVID-19 co-morbidity). This is real science—done and published by independent medical experts. We believe so strongly in the science we are providing links to these studies here. People should read them for themselves.
In sharp contrast to trying to protect the American public, the Government is doing all in its power to stop Xlear from simply telling the public about the science. It is profoundly ironic that the Government, which now constantly ignores science for political reasons, suggests that it is taking this action against Xlear to somehow protect the people. From what is the Government protecting Americans? From the facts. From the science. From their right to know.
Notwithstanding the Government’s litany of failures in protecting Americans from COVID-19, the Government seeks to pin blame on Xlear, a small company trying to help Americans understand there are other things that you can do that may help to provide additional layer of protection against COVID-19 for you, your friends, and your family. Get vaccinated, wear a mask, social distance, use common-sense, wash your hands—and wash your nose.
The Government tells people to wash their hands; Yet COVID-19 is an upper respiratory illness. Most COVID-19 infections start in the nose. It makes commonsense to wash your nose. People have been using nasal cleansing to fight respiratory illnesses going back thousands of years.
Xlear denies the Government’s allegations. We will vigorously defend against the Government’s case, and, in doing so, defend the science against politics, paternalism, and dogmaticism.
References:
Go , Camille Celeste, Pandav, Krunal, Sanchez-Gonzalez, Marcos A, Ferrer Gustavo, Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series (Nov. 2020), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645297/
Ferrer, Gustavo, et al, A Nasal Spray Solution of Grapefruit Seed Extract plus Xylitol Displays Virucidal Activity Against SARS-Cov-2 In Vitro, BioRxiv (Nov. 25, 2020), available at https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
;
Cannon, Mark, et al, In Vitro Analysis of the Anti-viral Potential of nasal spray constituents against SARS-CoV-2, bioRxiv 2020.12.02.408575, available at https://www.biorxiv.org/content/10.1101/2020.12.02.408575v2.full.pdf+html
;
Ferrer, G., et al., In Vitro Analysis of the Anti-viral Potential of Nasal Spray Constituents Xylitol and Grapefruit Extract plus against SARS-CoV-2, forthcoming in Journal Virus Research;
Kimura, K., et al., Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in nonhospitalized patients with coronavirus disease 2019. Int Forum Allergy Rhinol. 2020; 10: 1325– 1328, available at https://pubmed.ncbi.nlm.nih.gov/32914928/
.
Amy Baxter, et al., Rapid initiation of nasal saline irrigation to reduce morbidity and mortality in COVID+ outpatients: a randomized clinical trial compared to a national dataset, medRxiv 2021.08.16.21262044; doi:https://doi.org/10.1101/2021.08.16.21262044
available at https://www.medrxiv.org/content/10.1101/2021.08.16.21262044v2
;
Cegolon L, Javanbakht M, Mastrangelo G. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents [published online ahead of print, 2020 Aug 18]. Int J Hyg Environ Health. 2020;230:113605. doi:10.1016/j.ijheh.2020.113605;
Lipworth B, Chan R, RuiWen Kuo C. COVID-19: Start with the nose. J Allergy Clin Immunol. 2020;146(5):1214. doi:10.1016/j.jaci.2020.06.038; Spinelli, M. et al., Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity, The Lancet, Feb. 22, 2020, available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30982-8/fulltext
;
Radulesco T, Lechien JR, Saussez S, Hopkins C, Michel J. Safety and Impact of Nasal Lavages During Viral Infections Such as SARS-CoV-2. Ear Nose Throat J. 2021;100(2_suppl):188S-191S. doi:10.1177/0145561320950491.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005329/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures27.1.2026 07:00:00 CET | Press release
EIB-funding will accelerate development of the Histolog® Scanner and reinforce commercialisation efforts across Europe and United States SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372 billion in additional investment from 2021 to 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126080876/en/ The European Investment Bank (EIB) provides €20 million in financing to SamanTree Medical, a leader in surgical imaging innovation. The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures, R&D and continued development and advancement of the company's Histolog® Scanner, the first and only medical imaging device featuring massively
Ohana Development and Manchester City F.C. Sign Agreement to Launch Multi-Billion-Dirham Project in Abu Dhabi27.1.2026 07:00:00 CET | Press release
The 1.67 million square metre development is the world’s first Manchester City branded residential destination Ohana Development, a leading UAE real estate developer renowned for its luxury properties, has signed an agreement with Manchester City F.C. to launch ‘Manchester City Yas Residences by Ohana’, a first-of-its-kind branded residential community, set along Abu Dhabi’s Yas Canal waterfront. The partnership reflects a shared commitment to excellence, innovation and long-term value creation, reinforcing Abu Dhabi’s position as a global destination for world-class developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126122700/en/ Standing: HE Khaldoon Al Mubarak, Chairman of Manchester City Football Club. Left to right: Husein Salem, CEO of Ohana Development and Ferran Soriano, CEO of City Football Group. (Photo: AETOSWire). Spanning 1.67 million square metres, ‘Manchester City Yas Residences by Ohana’ draws on
Cirium Ascend Consultancy Named Appraiser of the Year at the Aviation 100 Awards for a Record 11th Time27.1.2026 07:00:00 CET | Press release
The fourth consecutive win recognizes Cirium’s position as the industry’s foremost provider of accurate, transparent aircraft valuations to the aviation finance and leasing sector. Cirium Ascend Consultancy has been named Appraiser of the Year 2026 in the Airline Economics Aviation 100 Global Leaders Awards, the team’s 11th title in 15 years. The Consultancy is a highly respected division of Cirium, the world’s most trusted source of aviation analytics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126679094/en/ AOTY Win The Appraiser of the Year award recognizes the aircraft appraisal provider that has demonstrated the greatest contribution to the industry over the past year. The fourth consecutive win reflects the trust placed in the Ascend Consultancy team and their work by their industry peers. The Aviation 100 Global Leaders Awards celebrate the best companies, individuals and transactions in the aviation finance an
Access Advance Extends HEVC Advance Rate Increase Deadline27.1.2026 02:00:00 CET | Press release
Provides New Licensees the Opportunity to Join at Current Royalty Rates Access Advance LLC today announced that the Licensors of HEVC Advance have approved an extension of the deadline for new Licensees to secure current royalty rates and caps through 2030. Companies that become Licensees of the HEVC Advance program on or before June 30, 2026 will secure current royalty rates for both ongoing royalties and calculation of royalties for past sales. This is a temporary postponement of the 25% increase in rates and caps applicable to Licensees who sign up after the previous December 31, 2025 deadline. The extension also applies to the Multi-Codec Bridging Agreement ("MCBA"), which provides a single discounted royalty rate structure for Licensees in both the HEVC Advance Patent Pool and the VVC Advance Patent Pool. Licensees who execute the MCBA by June 30, 2026 will benefit from royalty caps that match the royalty caps for the VVC Advance program. The extension follows Access Advance's rec
ANTA Sports to Acquire 29% Stake in PUMA, Further Strengthening Globalization Strategy27.1.2026 01:17:00 CET | Press release
Accelerates multi-brand globalization strategy and enhances ANTA’s global reach and competitivenessBrings proven growth track record to help unlock PUMA’s potential globally including in ChinaSupports PUMA’s management, strategy, brand autonomy and identityHas no current plans to make a takeover offer for PUMA ANTA Sports Products Limited (“ANTA Sports” or the “Company,” stock codes: 2020 (HKD counter) and 82020 (RMB counter), and its subsidiaries collectively the “Group”), today announced it has reached a share purchase agreement with Groupe Artémis, the investment company of the Pinault family, to acquire a 29.06% stake in PUMA SE, the company behind iconic global sports brand PUMA. The stake is valued at EUR 1.5 billion in cash. The transaction marks a significant step in ANTA Sports’ globalization strategy, further enhancing its reach, recognition and competitiveness in the global sporting goods market. The transaction is expected to close by the end of 2026, subject to relevant re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
